Reports
The following list of reports reflects the latest in findings and outcomes in medical research as presented at major medical meetings and published peer-reviewed medical journals. In this section you can view reports from important congresses as well as summaries of some recently published journal articles. Please let us know if you have a particular area of interest you would like to see covered.
46th Interscience Conference on Antimicrobial Agents and Chemotherapy
Expanding Options for Highly Treatment-experienced HIV-infected Patients
San Francisco, California / September 27-30, 2006
The newly released 96-week data from the pivotal RESIST (Randomized Evaluation of Strategic Intervention in Multi-drug Resistant Patients with Tipranavir) trials have confirmed that HIV infection can be suppressed indefinitely even in...
46th Interscience Conference on Antimicrobial Agents and Chemotherapy
New Antiretroviral Strategies Leading to Expanding Treatment Options
San Francisco, California / September 27-30, 2006
In the late-breaking trial of once-daily (q.d.) regimens, boosted fosamprenavir (FPV) was compared to boosted atazanavir (ATV), both of which were recently added to the list of IAS-USA Panel Guidelines of preferred protease inhibitors (PIs)...
XVI International AIDS Conference
Potency, Tolerability, Simplicity: Key Elements in Long-term HIV Treatment Success
Toronto, Ontario / August 13-18, 2006
The primary goal in HIV management is to achieve maximal and durable suppression of viral load (VL). Otherwise, keeping patients on suboptimal or failing regimens until they progress clinically—as they are forced to do in developing...
XVI International AIDS Conference
Towards Consensus on Boosted Protease Inhibitor Regimens as First-line HIV Treatment
Toronto, Ontario / August 13-18, 2006
The comparative non-inferiority study on the ritonavir-boosted protease inhibitors (PIs) fosamprenavir (FPV/r) and lopinavir (LPV/r), called the KLEAN (Kaletra Versus Lexiva with Epivir and Abacavir in ART-Naive Patients) trial, provided...
XVI International AIDS Conference
Towards Viral Load Undetectability in Highly Treatment-experienced Patients
Toronto, Ontario / August 13-18, 2006
Ten years after the introduction of highly active antiretroviral (ARV) therapy, the proportion of patients with HIV demonstrating multiple class resistance has been increasing. The progress in developing treatment options for highly...
12th International Congress on Infectious Diseases
Herpes Zoster and Pneumococcal Disease Vaccination: Improving Quality of Life of the Elderly
Lisbon, Portugal / June 15-18, 2006
Lisbon - Vaccination programs in adults, and particularly in older individuals, can be beneficial. It is estimated that 99% of the adult population has had varicella and older individuals in particular are susceptible to reactivation of the...
15th Annual Canadian Conference on HIV/AIDS Research
Achieving Viral Load Suppression in Treatment-experienced HIV Patients
Quebec City, Quebec / May 25-28, 2006
Speakers here agreed that choosing a regimen for the management of HIV infection requires considerable insight, foresight and prudence, especially for treatment-experienced patients, where the wrong choice can seriously compromise treatment...
15th Annual Canadian Conference on HIV/AIDS Research
Addressing Lipoatrophy and Efficacy in Treatment-experienced Patients
Quebec City, Quebec / May 25-28, 2006
Findings from RAVE In a presentation of the RAVE (Randomized Abacavir Viread Evaluation) data by Dr. Jonathan Cartledge, Mortimer Market Centre and University College London, UK, switching patients from a thymidine analogue to either the...
15th Annual Canadian Conference on HIV/AIDS Research (CAHR)
The Role of Pharmacogenetics in the Management of HIV Disease
Quebec City, Quebec / May 25-28, 2006
As discussed by Dr. Simon Mallal, clinical immunologist, Royal Perth Hospital, and Head, Centre for Clinical Immunology and Biomedical Statistics, Murdoch University, Perth, Australia, polymorphisms in both the host infected with HIV and...